• DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide, is now broadly available in the US for the treatment of Rett syndrome
• The new formulation was approved by the FDA in December 2025 and launched in the US on a limited basis in Q1 2026
• DAYBUE STIX allows caregivers to customize the administration by mixing it with a variety of water-based liquids

Neuren Pharmaceuticals (ASX: NEU) is pleased to announce that its partner Acadia Pharmaceuticals (Nasdaq: ACAD) has made DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation was approved by the US Food and Drug Administration (FDA) in December 2025 and launched in the US on a limited basis in Q1 2026. DAYBUE STIX is a powder for oral solution that caregivers can mix with a variety of water-based liquids such as juice, tea, lemonade, limeade, or liquid hydration, allowing them to customize the administration to their loved ones' taste. The product comes in individual packets that are easily portable. Initial feedback from a small group of caregivers following the limited launch revealed that more than 80% of early users reported satisfaction with DAYBUE STIX, highlighting the added flexibility and portability of this new formulation. The importance of flexible, patient-centered approaches was reinforced in a recent publication of expert recommendations for real-world use of trofinetide in Rett syndrome. A steering group comprised of experts based at International Rett Syndrome Foundation (IRSF)-designated centers of excellence (COEs) reached consensus recognizing trofinetide oral solution as part of the standard of care for individuals with Rett syndrome and advocating for the integration of trofinetide as part of the standard of care and comprehensive Rett syndrome management.